CEO Vas Narasimhan said the company has built up its U.S. inventories to help mitigate the impact of tariffs this year.

Industry-Wide Tariffs Loom Over the Healthcare Sector. Here Are 2 Stocks That Can Weather the Storm.

Vas Narasimhan, Novartis CEO, joins 'Money Movers' to discuss tariffs on pharmaceuticals, second quarter earnings and outlook ...

Johnson and Johnson beat Wall Street’s quarterly sales expectations and raised its full-year outlook, a show of confidence as ...

Drugmaker Swedish Orphan Biovitrum AB’s Chief Executive Officer Guido Oelkers said he doesn’t think tariff threats on the ...

Trump pharma and chip tariffs may start this month, sparking price hikes, inflation, and global trade ripples.

President Trump is readying plans for industry-specific tariffs to kick in alongside his country-by-country duties in two ...

W hen Donald Trump’s tariffs are mentioned, you might recall his “Liberation Day” duties on uninhabited islands, his on-again ...

A generous grace period would give drugmakers time to sidestep most of the pain of looming duties.

A 200% tariff rate — even with a delay — will have a detrimental effect on drug prices and profit margins, analysts warn.

After Trump's announcement, Commerce Secretary Howard Lutnick told CNBC that details on pharmaceutical tariffs would come at ...

President Trump said he was likely to impose tariffs on pharmaceuticals as soon as the end of the month, starting with a "low ...